Skip to content

ATTUNE Revision System in the Revision Total Knee Arthroplasty Population

Multi-Center Clinical Evaluation of the ATTUNE® Revision System in Revision Total Knee Arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03153475
Enrollment
400
Registered
2017-05-15
Start date
2017-05-30
Completion date
2029-03-31
Last updated
2026-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Revision Total Knee Arthroplasty

Keywords

Revision knee surgery, implant replacement

Brief summary

Five-year, Prospective, multi-center, non-randomized, non-controlled study of the ATTUNE® Revision total knee prostheses, utilizing the fixed bearing (FB) and rotating platform (RP) tibial component with the posterior stabilizing (PS) femoral component in revision total knee arthroplasty.

Detailed description

The study is designed as a non-comparative, worldwide, multi-center study with up to 30 sites that will intend to implant a total of 400 Subjects (200 PS RP and 200 PS FB) with the study devices. The follow-up period of 5 years was selected to cover both the early post-operative period as well as the medium term period which is a good indicator of longer term survivorship. The primary endpoint of survivorship at 5 years was selected to capture the time period during which the majority of revision failures occur while providing a good indication of long term survivorship. The secondary outcomes include commonly used measures of clinical performance that will allow for comparison with published literature. Additionally, patient reported outcomes, AORI bone defect classification , satisfaction and pain scores will be collected and analyzed. Male and female Subjects, age 22-80 years, inclusive, with a failed primary knee arthroplasty, including unicompartmental or failed previous revision TKA, who are suitable candidates for revision TKA using the ATTUNE® Revision system are eligible for enrollment in this study. The use of the ATTUNE Revision system includes both partial and complete revision surgical procedures, including implantation of revision components as the second stage within a two-stage treatment for infection.

Interventions

DEVICEATTUNE Revision Knee System in Revision Total Knee Arthroplasty

Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.

Sponsors

DePuy Orthopaedics
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Subject is male or female and between the ages of 22 and 80 years at the time of consent, inclusive. 2. Subject presents with a primary knee arthroplasty (primary TKA, unicompartmental) or prior revision TKA that requires a revision procedure of implanted tibial and/or femoral components. 3. The decision to perform a knee revision with the study device is regardless of the research. 4. Subject that is willing to give voluntary, written informed consent to participate in this clinical investigation and authorize the transfer of his/her information to the Sponsor 5. Subject is currently not bedridden 6. The devices are to be used according to the approved indications.Subject is able to read, and comprehend the Informed Consent Document as well as complete the required PROMs in either English or one of the available translations.

Exclusion criteria

1. The Subject is a woman who is pregnant or lactating. 2. Contralateral knee has already been enrolled in this study. 3. Subject had a contralateral amputation. 4. Subject is currently diagnosed with radicular pain from the spine that radiates into the limb to receive RTKA. 5. Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three (3) months. 6. Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims. 7. Subject, in the opinion of the Investigator, is a drug or alcohol abuser (in the last 5 years) or has a psychological disorder that could affect his/her ability to complete patient reported questionnaires or be compliant with follow-up requirements. 8. Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia. 9. Subject has a significant neurological or musculoskeletal disorder(s) or disease that may adversely affect gait or weight bearing activities (e.g., muscular dystrophy, multiple sclerosis, Charcot disease). 10. Subject has a medical condition with less than five (5) years life expectancy as determined by the Investigator. 11. Uncontrolled gout

Design outcomes

Primary

MeasureTime frameDescription
Survivorship5 YearsTo evaluate the 5 year survivorship using Kaplan-Meier survival analysis, with revision for any reason as the endpoint, for the ATTUNE® Revision TKA PS FB and PS RP configurations.

Secondary

MeasureTime frameDescription
Patient's Knee Implant Performance (PKIP)Baseline, 2 and 5 yr timepointsEvaluate change from preoperative baseline to 2 and 5 yr timepoints in functional outcomes, satisfaction and quality of life assessments, as measured using the PKIP patient reported outcome measure (overalll and subscores)
Knee Injury and Osteoarthritis Outcome Score Short form (KOOS-PS)Baseline, 2 year and 5 YearEvaluate change from preoperative baseline to 2 and 5 yr timepoints in functional outcomes assessments, as measured using the KOOS-PS patient reported outcome measures
American Knee Society ScoreBaseline, 2 year, 5 yearEvaluate change from preoperative baseline to 2 and 5 yr timepoints in functional outcomes assessments, patient satisfaction and expectations and clinical evaluations as measured using the AKS measure
EQ-5D-5LBaseline, 2 year and 5 yearEvaluate change from preoperative baseline to 2 and 5 yr timepoints in functional outcomes assessments, as measured using the EQ-5D-5L patient reported outcome measures
VAS Pain ScoreBaseline, 2 year and 5 yearEvaluate change from preoperative baseline to 2 and 5 yr timepoints in patient reported pain severity as measured using a modified VAS Pain Score (discrete numbers rather than a continual scale).
Patient SatisfactionBaseline, 2 year and 5 yearEvaluate change from preoperative baseline to 2 and 5 yr timepoints in patient reported satisfaction as measured using a Likert scale.
Adverse EventsIntraoperative, 6 weeks, 1 yr, 2 yrs., 3 yrs., 4 yrs., 5 yrs.Evaluate type and frequency of Adverse Events
Readmissions6 weeks, 1 yr, 2 yrs., 3 yrs., 4 yrs., 5 yrsEvaluate the timing, duration and reason for any readmissions stratified by adverse event type (operative site vs. systemic).
Survivorship1, 2, 3 and 4 yearsEvaluate survivorship of the ATTUNE® Revision TKA system for the PS FB and PS RP configurations and the combined PS FB and PS RP configurations using Kaplan-Meier survival analysis at 1, 2, 3, and 4 years.
Frequency of radiolucent line occurrence1, 2 and 5 yearsEvaluate ATTUNE® Revision TKA fixation through zonal radiographic analysis of the bone-implant interface at 1, 2 and 5 years after surgery compared to the first postoperative radiographs.
Anatomic Tibiofemoral Alignment1, 2 and 5 yearsEvaluate any changes in anatomic tibiofemoral alignment at 1, 2 and 5 yrs compared to the first postoperative radiographs.
femoral component alignment1, 2 and 5 yearsEvaluate any changes in femoral component alignment at 1, 2 and 5 yrs compared to the first postoperative radiographs.
Tibial component alignment1, 2 and 5 yearsEvaluate any changes in tibial component alignment at 1, 2 and 5 yrs compared to the first postoperative radiographs.
Restoration of joint lineFirst post-operative radiograph (1 day)Radiographically evaluate the restoration of joint line using the first postoperative radiographs according to the methodology of Figgie.

Countries

Australia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, New Zealand, Switzerland, United Kingdom, United States

Contacts

STUDY_DIRECTORSukhjeet Kaur

Sponsor GmbH

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 29, 2026